CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2019--
SYBX), a clinical stage company applying synthetic biology to
beneficial microbes to develop novel, living medicines, announced today
that the Company will release its first quarter 2019 financial results
after the market closes on Thursday, May 9, 2019. The press release will
be followed by a conference call at 5:00 pm ET, which will be open to
the public via telephone and webcast. During the conference call, the
Company will review its financial results and provide a corporate update.
The conference call dial-in numbers are (844) 815-2882 for domestic
callers and (213) 660-0926 for international callers. The conference ID
number for the call is 2154739. Participants may access the live webcast
via a link on the Synlogic website in the Events
Calendar of the Investors and Media section. For those unable to
participate in the conference call or webcast, a replay will be
available for 30 days on the Company's website.
Synlogic is pioneering the development of a novel class of living
medicines, Synthetic Biotic medicines, based on its proprietary drug
development platform. Synlogic leverages the tools and principles of
synthetic biology to genetically engineer beneficial microbes to perform
or deliver critical functions missing or damaged due to disease.
Synthetic Biotic medicines are designed to act locally and have a
systemic effect to address disease in patients. Synlogic’s two lead
programs, SYNB1020 and SYNB1618, are orally administered and target
hyperammonemia as a result of liver damage or genetic disease, and
phenylketonuria, respectively. Synlogic is also developing SYNB1891 as
an intratumorally-administered Synthetic Biotic medicine for the
treatment of cancer. In addition, the company is leveraging the broad
potential of its platform to create additional Synthetic Biotic
medicines for the treatment of liver disease, as well as inflammatory
and immune disorders including Synlogic’s collaboration with AbbVie to
develop Synthetic Biotic-based treatments for inflammatory bowel disease
(IBD). For more information, please visit www.synlogictx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005712/en/
Source: Synlogic, Inc.
Elizabeth Wolffe, Ph.D.